400+ pharmaceutical companies specializing in bulk drugs, API, Formulations and medical devices in Tamil Nadu.
Approximately 88,000 registered pharmacists in the State.
Witnesses a presence of global pharmaceuticals and medical device manufacturers such as Air Liquide, Trivitron Healthcare, Titan Corporation. Public Companies such as IDPL and HLL Biotech also have manufacturing plants in Chennai.
70+ institutes providing a range of pharma & biotech degrees and diplomas.
Home to numerous top-quality institutes in the sector covering CMC, VIT (Vellore), Dr. MGR Medical University, IIT, Centre for Biotechnology, Anna University (Chennai), JSS College (Ooty), Madurai Medical College (Madurai), TNAU, PSG College of Pharmacy (Coimbatore).
To support R&D and innovation, Tamil Nadu has numerous University Innovation Clusters (UICs) at TNAU (Coimbatore), Anna University (Chennai), Bio-incubators (Bio-Nest) in IIT-M (Chennai), VIT-TBI (Vellore), PSG-STEP (Coimbatore), and Golden Jubilee Biotech Park for Women, (Chennai)
largest Pharmaceutical Manufacturing State in the Country
National Pharma Production
$ 423 m
Pharmaceuticals exports from Tamil Nadu
Agro Technology Research Stations Supporting in Biotech
Allowed Under Automatic Route
Pharma and Biotech Cluster in Tamil Nadu
Tamil Nadu’s Pride
- India imports > 70% of its API requirements.
- Huge opportunity to reduce import dependency and increase the capabilities of domestic manufacturers in Tamil Nadu.
- Tamil Nadu is boosting infrastructure to cater to Bulk Drug Manufacturers with a State-of-the-art bulk drug park planned for the State of Tamil Nadu.
- Contract Manufacturing is growing at the rate of 20% in India and poised for a huge take-off.
- Numerous Manufacturers present in Tamil Nadu to collaborate with.
- The healthcare market is expected to reach US$ 372 Billion by 2022
- Launch of Ayushman Bharat, the largest Government funded healthcare scheme is galvanizing the healthcare sector
- Tamil Nadu has offered special incentives for manufacture of medical consumables/ equipment in the post COVID-19 era
- India is among the top 12 biotech destinations in the world and ranks second in Asia, after China
- The sector is valued at $64 bn (in 2019) and expected to touch $150 bn by 2024-25
- India’s share in the global biotechnology market is also expected to reach 19% in 2024-25 from its share of 3% (in 2017)
- Tamil Nadu’s Biotech journey began in the early 2000’s with the formulation of a high-powered committee headed by Prof. M.S Swaminathan to evolve a comprehensive Biotech policy for the State of Tamil Nadu
- Tamil Nadu is home to state-of-the-art facilities specifically earmarked for the development of the Biotech Sector
- With many lucrative factors anchoring the vaccine business, the current market of USD 1 billion could easily double to USD 2 billion in less than 5 years
- Bioinformatics is one of the fastest-expanding fields in India's biotechnology sector
- A total of 2,669 biotech start-ups are incorporated in India. Out of them 140 (5.25%) were from Tamil Nadu. There is scope for GoTN to support more startups
- Bioactive Therapeutics Proteins
- Stem Cell research
- Cell engineering
- Cell based Therapeutics
- Animal Biotechnology
- Clinical trials & outsourcing
- Indian MDT market was estimated at approximately INR 41,216 crore (US$5.3 billion) in 2019 and is expected to grow to INR 63,028 crore (US$8.9 billion) by 2025 at a CAGR 9.4 percent
- Tamil Nadu is setting up a Medi-Park close to Chennai spread across 330 acres to cater to the requirements of Medical Device companies.
- Orthopaedics & prosthetics equipment market is estimated to register a CAGR of 8.0 percent between 2018 -23
- Portable aids and therapeutic appliances are estimated to witness a CAGR of 7.5 percent and 7.6 percent respectively
- Electrodiagnostic apparatus is estimated to grow at a CAGR of 7.8 percent between 2018-23 , with MRI apparatus leading the growth. Within imaging parts, contrast media is projected to witness highest growth
- Blood-grouping reagents and surgical gloves is projected to grow at a CAGR of 8.2 percent between 2018-23, followed by suturing materials at a CAGR of 8.1 percent
- While the capital equipment sub-segment is estimated to grow at a CAGR of 9.3 percent between 2018-23, instruments and supplies is projected to grow at a CAGR of 9.5 percent during forecast period.